TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01195025

Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.

Intervention type: DRUG
Group type: OTHER
Intervention: colloid+acetated Ringer
Description: Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive hemoglobin with pulse-oximeter (SpHb)
Description: Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
Study: NCT02393092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Violence Awareness
Description: The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Violence Prevention
Description: The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Violence Prevention
Description: The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging Leaders: East End curriculum
Description: The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
Study: NCT02748369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: Somatostatin infusion to create a low insulin state.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon infusion in the setting of ongoing somatostatin.
Study: NCT03319628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT02237820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6 mg/day of Oral Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 40 mg/day of Oral Prednisone
Study: NCT03394547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allay
Description: pulsed shortwave therapy treatment for painful periods

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
Study: NCT00003659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients \> 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
Study: NCT01857934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu14.18K322A
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell harvest
Description: Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Description: The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
Study: NCT03319628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: upifitamab rilsodotin
Description: XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.~For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536
Study: NCT04585685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A 12-session cognitive behavioral therapy for posttraumatic stress disorder
Study: NCT05076721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case-based discussion training
Description: The participants in the conventional group will only do a case-based discussion in implementing one-hour bundle sepsis
Study: NCT04585685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A 12-session cognitive behavioral therapy for posttraumatic stress disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A 12-session cognitive behavioral therapy for posttraumatic stress disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: A 12-session cognitive behavioral therapy for posttraumatic stress disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Therapy
Description: A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Therapy
Description: A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Therapy
Description: A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Therapy
Description: A 6-session mindfulness based therapy for posttraumatic stress disorder aimed at enhancing self-compassion
Study: NCT03751735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
Study: NCT04677270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital problem solving tool
Description: Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital problem solving tool
Description: Digital problem solving tool - adapted for practical and emotional problems during the COVID-19 pandemic
Study: NCT00473694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Administered as an intravenous (IV) infusion
Study: NCT01546129

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Dianatal Obstetric Gel (Cross-linked polyacrylic acid)
Description: Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
Study: NCT00473694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vecuronium
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vecuronium
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopyrrolate
Description: Administered as an IV infusion
Study: NCT01546129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dianatal Obstetric Gel (Cross-linked polyacrylic acid)
Description: Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
Study: NCT03206658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg
Description: A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
Study: NCT05928143

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional corticotomy
Description: A flap covering the alveolar process will be elevated. Perforations will be done using surgical burs, and then the flap will be returned, and sutures will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless corticotomy
Description: Some incisions will be made in the mucosa of the alveolar process. Then these incisions will allow the working head of the piezotome to cut the bone in grooves. The whole procedure will not require flap elevation and replacement.
Study: NCT04153630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells derived from bone marrow (BM-MSCs)
Description: Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
Study: NCT03932955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC-19PD1 CAR-T cells
Description: T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
Study: NCT01881555

Intervention type: PROCEDURE
Group type: OTHER
Intervention: invasive coronary angiography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional testing by fractional flow reserve measurement
Description: Functional testing by fractional flow reserve measurement
Study: NCT03993509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the right dlPFC
Description: A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS to the right dlPFC
Description: A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
Study: NCT03702920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMT + PE-A 5%
Description: Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
Study: NCT01157169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 8 mg Sublingual Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: 8 mg Sublingual Tablets
Study: NCT00981435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 1%
Description: Prednisolone 1% to lasered eye 4 times/day for 4.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: Artificial saline tears to lasered eye 4 times/day for 4.5 days
Study: NCT01351662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Self Management Program
Description: Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
Study: NCT03016234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4\~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
Study: NCT00839163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xarelto (Rivaroxaban, BAY59-7939)
Description: 40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin/Vitamin K-Antagonist
Description: Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
Study: NCT05598086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid
Description: local infiltration of TXA or normal saline in the post-operation would

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: local infiltration of TXA or normal saline in the post-operation would
Study: NCT00929292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modilac Dahlia 1
Description: Infant formula used for non breastfed children with colic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Modilac 1
Description: Infant formula used for non breastfed children
Study: NCT01981187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
Study: NCT04047030

Intervention type: OTHER
Intervention: None- Observational Study
Description: No Intervention

Intervention type: OTHER
Intervention: None- Observational Study
Description: No Intervention
Study: NCT03843580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optiflow
Description: we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy